Estados Unidos · Plataformas y datos · Briefing.com

Disc Medicine Surges as Phase 3 APOLLO Trial Meets All Primary and Secondary Endpoints (IRON)

Publicado por Briefing.com · Estados Unidos hace 11 d

Disc Medicine (IRON) is surging today after announcing that its pivotal Phase 3 APOLLO trial of bitopertin met both co-primary and all secondary endpoints in patients with…

Leer el artículo completo en Briefing.com Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.briefing.com)

Disc Medicine Surges as Phase 3 APOLLO Trial Meets All Primary and Secondary Endpoints (IRON)

También te puede interesar

Quad Graphics Q3 Earnings Call Highlights

Is SpaceX Stock a Buy After Plummeting 28%?

First Business outlines ~10% annual loan growth and sees NIM staying above 3.60%–3.65% long-term range

Hedge fund Arini sells $800 million in debt as losses mount - WSJ

Has the tech bubble burst? Why the Nasdaq’s rough ride looks eerily like 2000.

Elon Musk Warns Of AI Shakeout, While Zuckerberg, Pichai, Nadella, Jassy Discuss The Costs: MAG 7 Voices This Week

Disc Medicine Surges as Phase 3 APOLLO Trial Meets All Primary and Secondary Endpoints (IRON)

Compartir

También te puede interesar

Quad Graphics Q3 Earnings Call Highlights

Is SpaceX Stock a Buy After Plummeting 28%?

First Business outlines ~10% annual loan growth and sees NIM staying above 3.60%–3.65% long-term range

Hedge fund Arini sells $800 million in debt as losses mount - WSJ

Has the tech bubble burst? Why the Nasdaq’s rough ride looks eerily like 2000.

Elon Musk Warns Of AI Shakeout, While Zuckerberg, Pichai, Nadella, Jassy Discuss The Costs: MAG 7 Voices This Week